A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients with Esophageal Adenocarcinoma.

Alexander J ByunRachel A GrosserJennie K ChoeNabil P RizkLaura H TangDaniela MolenaKay See TanDavid RestleWaseem CheemaAmy ZhuHans GerdesArnold J MarkowitzManjit S BainsValerie W RuschDavid R JonesPrasad S Adusumilli

Published in: Annals of surgery (2023)

Pre-treatment tumor mesothelin expression is prognostic of OS for patients with locally advanced esophageal ADC, whereas serum SMRP is not a reliable biomarker for monitoring treatment response or recurrence.

Keyphrases

locally advanced
clinical trial
squamous cell carcinoma
rectal cancer
neoadjuvant chemotherapy
poor prognosis
radiation therapy
phase ii study
computed tomography
magnetic resonance
open label
phase ii
study protocol
lymph node
randomized controlled trial
double blind